Compounds > ls-102
Page last updated: 2024-11-13

ls-102

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID118518043
SCHEMBL ID17265617
MeSH IDM0585032

Synonyms (11)

Synonym
LS-102 ,
SCHEMBL17265617
HY-135844
CS-0114389
6-n-(1,3-benzoxazol-6-yl)-4-n-[(1s)-1-cyclohexylethyl]-2-n-ethyl-2-n-[2-(ethylamino)ethyl]-1,3,5-triazine-2,4,6-triamine
MS-28237
1456891-34-1
(s)-n2-(benzo[d]oxazol-6-yl)-n4-(1-cyclohexylethyl)-n6-ethyl-n6-(2-(ethylamino)ethyl)-1,3,5-triazine-2,4,6-triamine
PD157582
Z4609391014
AKOS040733622

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Oral LS-102 produced a pharmacokinetic profile different from AGS IV with higher bioavailability, while the toxic tolerance was similar to previous estimates."( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102).
Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)		1.23

Pharmacokinetics

Oral LS-102 produced a pharmacokinetic profile different from AGS IV with higher bioavailability. The toxic tolerance was similar to previous estimates.

ExcerptReferenceRelevance
" The objective of this study was to investigate the intestinal absorption, main pharmacokinetic parameters and acute toxicity of LS-102 in rodents compared with AGS IV."( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102).
Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)		0.92
" The plasma concentrations were detected by a validated UHPLC-MS/MS method, and pharmacokinetic parameters were calculated using a compartmental model."( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102).
Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)		0.71
"Oral LS-102 produced a pharmacokinetic profile different from AGS IV with higher bioavailability, while the toxic tolerance was similar to previous estimates."( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102).
Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)		1.23
"The objective of this study was to investigate the pharmacokinetic properties of LS-102 after single-dose, oral administration in beagle dogs by developing and validating an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method."( Determination of a astragaloside IV derivative LS-102 in plasma by ultra-performance liquid chromatography-tandem mass spectrometry in dog plasma and its application in a pharmacokinetic study.
Cheng, Y; Ding, LS; He, Y; Luo, P; Qing, LS; Sun, WX; Xie, J; Zhang, ZF, 2019)		1

Bioavailability

ExcerptReferenceRelevance
" However, its disappointing clinical application is mainly caused by its very low solubility in biologic fluids, resulting in poor bioavailability after oral administration."( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102).
Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)		0.71
" However, it is disappointing that the in vivo solubility of astragaloside IV and its bioavailability after oral administration are very low."( The Astragaloside IV Derivative LS-102 Ameliorates Obesity-Related Nephropathy.
Li, Z; Liu, Y; Luo, P; Wu, J; Yang, W; Yang, Y, 2022)		1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.67 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index57.44 (26.88)
Search Engine Supply Index3.73 (0.95)

This Compound (29.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzoxazoles
1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.		3.26501,3-benzoxazoles;
mancude organic heterobicyclic parent
astragaloside a
[no description available]		2.9430
beta-escin
[no description available]		2.9430
ConditionIndicatedRelationship StrengthStudiesTrials
Diabetic Glomerulosclerosis
[description not available]		02.4110
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		02.4110
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		07.4110
Diffuse Parenchymal Lung Disease
[description not available]		02.1110
Lung Diseases, Interstitial
A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.		02.1110
Rheumatoid Arthritis
[description not available]		02.0710
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.0710